Sugi Predict

Sugi Predict / Compounds / SCHEMBL1334813

SCHEMBL1334813

SCHEMBL1334813

Nc1ccc2cc[nH]c2n1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ AXL P30530 2/20 0.45
▸ NUDT1 P36639 1/20 0.45
▸ BRD4 O60885 1/20 0.39
▸ DYRK1A Q13627 1/20 0.38
▸ CA5A P35218 1/20 0.38
▸ BACE1 P56817 7/20 0.38
▸ NOS2 P35228 2/20 0.38
▸ NCF1 P14598 2/20 0.38
▸ APP P05067 1/20 0.37
▸ PLAU P00749 2/20 0.35
▸ ADORA2A P29274 1/20 0.35
▸ ADORA1 P30542 1/20 0.35
▸ NOS3 P29474 1/20 0.34
▸ NOS1 P29475 1/20 0.34
▸ NCK1 P16333 1/20 0.33
▸ CDK8 P49336 1/20 0.33
▸ MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29365560 0.76 AXL (0.45) AXLNUDT1BRD4APPADORA2A
SCHEMBL10776 0.76 AXL (0.45) AXLNUDT1BRD4APPADORA2A
SCHEMBL31276718 0.71 AXL (0.45) AXLNUDT1BRD4DYRK1AAPP
SCHEMBL684703 0.71 AXL (0.45) AXLNUDT1BRD4APPCDK8
SCHEMBL29362558 0.71 MAPK1 (0.45) AXLNUDT1BRD4DYRK1AAPP
SCHEMBL414134 0.71 MAPK1 (0.45) AXLNUDT1BRD4DYRK1AAPP
SCHEMBL4063067 0.71 AXL (0.45) AXLNUDT1BRD4DYRK1AAPP
SCHEMBL343400 0.71 ADORA2A (0.57) AXLNUDT1BRD4APPADORA2A
SCHEMBL963531 0.71 AXL (0.45) AXLNUDT1BRD4DYRK1AAPP
SCHEMBL12798351 0.71 AXL (0.45) AXLNUDT1BRD4DYRK1AAPP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117045659-B Application of 7-azaindol-6-amine CLIP1-LTK fusion protein regulator 浙江大学 2024-05-10 — — CN claimed
CN-117045659-A Application of 7-azaindol-6-amine CLIP1-LTK fusion protein regulator 浙江大学 2023-11-14 — — CN claimed
WO-2020149715-A1 PYRROLOPYRIDINE DERIVATIVE AND USE THEREOF IN PREVENTION AND TREATMENT OF PROTEIN KINASE-RELATED DISEASE 주식회사 보로노이 2020-07-23 — — WO claimed
CN-110669058-A Tricyclic quinolone carboxylic acid and preparation method thereof 江西农业大学 2020-01-10 — — CN claimed
US-8247556-B2 Method for preparing 6-substituted-7-aza-indoles AMGEN INC. (US) 2012-08-21 — — US claimed
CN-102134240-A Synthesis method of 6-fluorine-7-azaindole JIAXING EPOCHEM PHARMTECH CO LTD 2011-07-27 — — CN claimed
US-12391676-B2 BRD4-JAK2 inhibitors H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2025-08-19 — — US disclosed
US-12358886-B2 Heterocyclic compounds for use in the treatment of cancer ARTIOS PHARMA LIMITED (GB) 2025-07-15 — — US disclosed
CN-117045659-B Application of 7-azaindol-6-amine CLIP1-LTK fusion protein regulator 浙江大学 2024-05-10 — — CN disclosed
CN-117045659-B Application of 7-azaindol-6-amine CLIP1-LTK fusion protein regulator 浙江大学 2024-05-10 — — CN disclosed
CN-117045659-B Application of 7-azaindol-6-amine CLIP1-LTK fusion protein regulator 浙江大学 2024-05-10 — — CN disclosed
WO-2023226964-A1 HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF DANATLAS PHARMACEUTICALS CO., LTD. (CN) 2023-11-30 — — WO disclosed
CN-117045659-A Application of 7-azaindol-6-amine CLIP1-LTK fusion protein regulator 浙江大学 2023-11-14 — — CN disclosed
WO-2008080015-A2 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON, INC. (US) 2008-07-03 — — WO disclosed
EP-1309590-B1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PFIZER ITALIA SRL (IT) 2007-09-19 — — EP disclosed
US-20070185171-A1 Compounds and methods of use AMGEN INC. 2007-08-09 — — US disclosed
WO-2007076423-A2 INHIBITORS OF Akt ACTIVITY SMITHKLINE BEECHAM CORPORATION (US) 2007-07-05 — — WO disclosed
US-20030004350-A1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PHARMACIA & UPJOHN (IT) 2003-01-02 — — US disclosed
US-6486322-B1 Azaindole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA ITALIA S.P.A. (IT) 2002-11-26 — — US disclosed
US-6335342-B1 1H-PYRROLO(2,3-B)PYRIDINE DERIVATIVES; ANTICARCINOGENIC, ANTIMETASTASIS, ANTITUMOR AND ANTIPROLIFERATIVE AGENTS PHARMACIA & UPJOHN S.P.A. (IT) 2002-01-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12391676-B2 BRD4-JAK2 inhibitors BRD4, BICRA, JAK2 AXL 2245/4885NUDT1 4087/4885BRD4 1/4885
US-20070185171-A1 Compounds and methods of use VHL, PGF, PTGIS AXL 1711/4885NUDT1 346/4885BRD4 2853/4885
US-20030004350-A1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS FFAR4, AZI2, CNKSR1 AXL 307/4885NUDT1 342/4885BRD4 136/4885
US-12358886-B2 Heterocyclic compounds for use in the treatment of cancer SDHA, DPYD, TP53 AXL 1468/4885NUDT1 95/4885BRD4 396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.